Suchergebnisse - "Buti, Maria"

PubPharm (8)

1

Real-world effectiveness of voxilaprevir/velpatasvir/sofosbuvir in patients following DAA failure

enthalten in: JHEP reports : innovation in hepatology | 2024

von Graf, C. | D'Ambrosio, R. | Degasperi, E. | +12

2

Real-world treatment outcome with protease inhibitor direct-acting antiviral in advanced hepatitis C cirrhosis : a REAL-C study

enthalten in: Hepatology international | 2023

von Wong, Y. | Tran, S. | Huang, C. | +81

3

Real-world treatment outcome with protease inhibitor direct-acting antiviral in advanced hepatitis C cirrhosis: a REAL-C study

enthalten in: Hepatology international | 2023

von Wong, Y. | Tran, S. | Huang, C. | +81

4

Impact of the COVID-19 pandemic on hepatitis B and C elimination : An EASL survey

enthalten in: JHEP reports : innovation in hepatology | 2022

von Kondili, L. | Buti, M. | Riveiro-Barciela, M. | +4

5

Barriers to linkage to care in hepatitis C patients with substance use disorders and dual diagnoses, despite centralized management

enthalten in: Therapeutic advances in gastroenterology | 2021

von Grau-López, L. | Marcos-Fosch, C. | Daigre, C. | +11

6

aMAP risk score predicts hepatocellular carcinoma development in patients with chronic hepatitis

enthalten in: Journal of hepatology | 2020

von Fan, R. | Papatheodoridis, G. | Sun, J. | +39

CommentIn: J Hepatol. 2021 Apr;74(4):994-996. - PMID 33340577

7

Non-invasive prediction of liver-related events in patients with HCV-associated compensated advanced chronic liver disease after oral antivirals

enthalten in: Journal of hepatology | 2020

von Pons, M. | Rodríguez-Tajes, S. | Esteban, J. | +8

CommentIn: J Hepatol. 2020 Aug;73(2):472-473. - PMID 32493575

8

Glecaprevir/pibrentasvir for 8 weeks in treatment-naïve patients with chronic HCV genotypes 1-6 and compensated cirrhosis : The EXPEDITION-8 trial

enthalten in: Journal of hepatology | 2020

von Brown, R. | Buti, M. | Rodrigues, L. | +19

CommentIn: J Hepatol. 2020 Mar;72(3):389-390. - PMID 31703944

1
[1]